Robert (Chip) Hance 

CEO

An industry veteran with more than 35 years’ experience in cardiovascular, diabetes and diagnostics devices, Chip Hance is CEO of Regatta Medical, an investment partnership with GTCR, a leading private equity firm.  Regatta is focused on building specialty technology companies with unique relevance to the medical device industry.  Examples of investments include Resonetics and Biocoat.

Hance was recently named Chairman of the Medical Device Innovation Consortium (MDIC) and has been active for years as the board champion for the Early Feasibility Study (EFS) clinical trial collaborative initiative.  Hance is also on the boards of several Ireland-based cardiovascular startups and is an active seed investor.

 Prior to Regatta, Hance was the CEO of Creganna Medical, an Ireland based supplier to the minimally invasive medical device industry.  Hance led the sale of Creganna Medical to TE Connectivity, a large industrial manufacturer, in 2016.

In 2012-13, Hance was an Entrepreneur-in-Residence at CDRH within the FDA.  He co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.

Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.

Mark Weishaar

Vice President, Business Development

Mark has a long history of corporate development and mergers & acquisitions work within the medical device and invitro diagnostics industries.  Most recently the focus has been on portfolio companies Biocoat and Resonetics with over fifteen transactions completed in the last five years including acquisitions, corporate carve-outs, a joint venture, options to acquire and providing debt financing.

Prior to Regatta Medical, Mark spent over 30 years at Abbott Labs where in the later portion he managed acquisitions and business development for Abbott's medical device and diagnostic businesses. Key actions included items such as the establishment and development of Abbott Vascular, the entry/expansion in Ophthalmic devices, the expansion and subsequent divestiture of Abbott Spine. Earlier in his Abbott career, Mark held a variety of positions across marketing, R&D, engineering, and operations.

Mark earned a bachelor’s degree in Industrial Engineering from the Univeristy of Illinois and a master’s degree in Business Administration from Northwestern’s Kellogg Business School.